Emerging drug therapies for preventing spontaneous preterm labor and preterm birth

Abstract

Preterm birth (PTB) is the main cause of neonatal mortality and morbidity in the developed world. Historically, the approach for the prevention of PTB has been reactive rather than proactive. With the introduction of new screening tests and a greater emphasis on prevention rather than treatment, a number of new approaches have been introduced that show promise. Progesterone, which is responsible for myometrial quiescence in pregnancy and is used in women with a previous history of PTB, is associated with a significant reduction in the incidence of PTB and low birth weight. Infection is an important cause of PTB in ≤ 40% of women. The appropriate antibiotics administered early in pregnancy to women with abnormal genital tract flora have been associated with a 40 – 60% reduction in the incidence of PTB. Although there has been debate regarding the benefits of nutritional supplementation for the prevention of many complications of pregnancy, recent evidence suggests that fish oil supplementation can be shown to reduce the incidence of PTB in women at risk of PTB. Although these three proactive, preventative approaches show promise, further research is needed to establish the best agent, the optimum gestational age at commencement and cessation, the ideal candidate patient to achieve a response and the long-term feto–maternal benefits and/or side effects.

Keywords::

• clindamycin
• docosa-hexanoic acids
• eicosa-pentanoic acids
• n-3 fatty acids
• nutritional supplementation
• omega-3
• premature
• preterm birth
• preterm labor
• progesterone

Acknowledgement

The authors thank P Mills for help with preparation of the manuscript.